CURRICULUM VITAE

김남훈

고려대학교 안암병원, 고려대학교 의과대학

[학력]

2004	고려대학교 의과대학 학사
2009	고려대학교 의과대학 석사
2015	고려대학교 의과대학 박사



2023-현재	한국지질·동맥경화학회 간행위원회 간사
2023-현재	한국지질·동맥경화학회 학술위원회 위원
2024-현재	대한당뇨병학회 학술위원회 간사
2021-현재	대한내분비학회 기획위원회 간사

[관심분야]

Lipid metabolism, diabetes therapeutics, obesity

[논문]

- 1. Kim JY, Kim NH. Initial Combination Therapy in Type 2 Diabetes. Endocrinol Metab (Seoul). 2024 Feb;39(1):23-32.
- 2. Kim NH, Kim JY, Choi J, Kim SG. Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study. Eur Heart J Cardiovasc Pharmacother. 2024 Feb 23;10(2):118-127.
- 3. Kim JY, Choi J, Kim SG, Kim NH. Comparison of on-Statin Lipid and Lipoprotein Levels for the Prediction of First Cardiovascular Event in Type 2 Diabetes Mellitus. Diabetes Metab J. 2023 Nov;47(6):837-845.
- 4. Kim KJ, Son S, Kim KJ, Kim SG, Kim NH. Weight-adjusted waist as an integrated index for fat, muscle and bone health in adults. J Cachexia Sarcopenia Muscle. 2023 Oct;14(5):2196-2203.
- 5. Kim JY, Choi J, Kwon Y, Park S, Kim SG, Kim NH. Serum fibroblast growth factor 1 and its association with pancreatic beta cell function and insulin sensitivity in adults with glucose intolerance. Front Endocrinol (Lausanne). 2023 May 22;14:1198311.



Unraveling the triglycerides puzzle: unifying insights and addressing discrepancies between Korean big-data and RCT findings

Nam Hoon Kim

Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Korea

We have observed the results from RCTs and CV-OTs of TG lowering therapies, which mostly failed to prove cardioprotective effects as a single drug. However, several cohort studies within a real world setting, in contrast, consistently showed that Tg lowering therapies, including fenofibrate and omega-3 fatty acids, had a beneficial role in the prevention of atherosclerotic diseases or cardiovascular

outcomes. First of all, there might be publication bias, but considering that, differences evidently are likely to exist between RCTs and RWEs of this topic. I will summarize and discuss about the reasons about that, including the real meaning of hyperTG, impact of TG variability on cardiovascular risk, different strategies to reduce hyperTG, and ethnic difference.